what stimulates glp 1 production GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes glp-1_analogs [TUSOM | Pharmwiki]

GLP-1 Drug Semaglutide Substantially Reduced Heavy Alcohol Consumption and Weight in Patients with Alcohol Use Disorder and Obesity Researchers have reported positive results in the first clinical trial testing the diabetes and weight-loss medicine semaglutide (Ozempic, Wegovy) in treatment-seeking patents with alcohol use disorder (AUD) who were also obese

Marrs KA (1996)

There is no published RCT and no long-term human safety data

Lifestyle Factors Complementary strategies for optimal metabolic outcomes

It may not be suitable for individuals with liver or kidney disease, as these conditions can affect berberine metabolism and clearance